Announcement PDF ASX RELEASE 25 October 2023 Dear Shareholders 2023 ANNUAL GENERAL MEETING The Company’s annual general meeting is scheduled to be held at the offices of RSM Australia, Floor 21, 55 Collins Street, Melbourne, 3000, and as a virtual meeting on Wednesday, 29 November 2023 at 9:00am (AEST) (Meeting). In accordance with new provisions under the Corporations Act, the Company will not be sending hard copies of the Notice of Meeting to shareholders unless a shareholder has previously requested a hard copy. The Notice of Meeting can be viewed and downloaded from https://paradigmbiopharma.com/performance-progress/ Please also refer to the Online Meeting Guide attached to the Notice of Meeting for details on how to participate in the Meeting. The Company strongly encourages Shareholders to lodge a directed proxy form prior to the meeting. Questions should also be submitted in advance of the Meeting as this will provide management with the best opportunity to prepare for the Meeting, for example by preparing answers in advance to Shareholders questions. However, votes and questions may also be submitted during the Meeting. Further details of how to participate in the Meeting are set out in the Online Meeting Guide. Please find below links to important Meeting documents: Notice of Meeting and Explanatory Memorandum: https://paradigmbiopharma.com/performance-progress/ Registration and Voting guide: https://www.automicgroup.com.au/virtual-agms/ Alternatively, a complete copy of the important Meeting documents has been posted on the Company’s ASX market announcements page. If you have nominated an email address and have elected to receive electronic communications from the Company, you will also receive an email to your nominated email address with a link to an electronic copy of the important Meeting documents. In order to receive electronic communications from the Company in the future, please update your Shareholder details online at www.investor.automic.com.au/#/home and log in with your unique shareholder identification number and postcode (or country for overseas residents), Paradigm Biopharmaceuticals Ltd | ABN: 94 169 346 963 Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA where you can find on your enclosed personalised proxy form. Once logged in you can also lodge your proxy vote online by clicking on the “Vote” tab. If you are unable to access any of the important Meeting documents online, please contact the Company Secretary, Abby Macnish Niven, on +61 8 6382 1805 or via email at amacnish@paradigmbiopharma.com The Company will notify Shareholders via the Company’s website at https://paradigmbiopharma.com and the Company’s ASX Announcement Platform at asx.com.au (ASX:PAR) if changing circumstances impact the planning or arrangements for the Meeting. This announcement is authorised for market release by the Board of Paradigm Biopharmacueticals Limited. Sincerely, Abby Macnish Niven Company Secretary PARADIGM BIOPHARMACEUTICALS LTD ACN 169 346 963 NOTICE OF ANNUAL GENERAL MEETING Notice is given that the Meeting will be held at: TIME: 9.00am AEDST DATE: Wednesday 29th November 2023 PLACE: RSM Australia, Floor 21, 55 Collins Street, Melbourne VIC 3000 and via a virtual meeting The business of the Meeting affects your shareholding and your vote is important. This Notice should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting. The Directors have determined pursuant to Regulation 7.11.37 of the Corporations Regulations 2001 (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 7.00pm (AEDST) on Monday 27 November 2023. BUSINESS OF THE MEETING AGENDA 1. FINANCIAL STATEMENTS AND REPORTS To receive and consider the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Director’s report, the Remuneration Report and the auditor’s report. 2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT To consider and, if thought fit, to pass, with or without amendment, the following resolution as a non-binding resolution: “That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company’s annual financial report for the financial year ended 30 June 2023.” Note: the vote on this Resolution is advisory only and does not bind the Directors or the Company. A voting prohibition statement applies to this Resolution. Please see below. 3. RESOLUTION 2 – RE-ELECTION OF DIRECTOR – DR DONNA SKERRETT To consider and, if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution: “That, for the purpose of clause 13.3 of the Constitution, Listing Rule 14.4 and for all other purposes, Dr Donna Skerrett, a Director, retires by rotation, and being eligible, is re-elected as a Director.” 4. RESOLUTION 3 – APPROVAL OF 7.1A MANDATE To consider and, if thought fit, to pass the following resolution as a special resolution: “That, for the purposes of Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in the Explanatory Statement.” 5. RESOLUTION 4 – ADOPTION OF EMPLOYEE PERFORMANCE RIGHTS PLAN To consider and, if thought fit, pass with or without amendment, the following resolution as an ordinary resolution: "That, for the purposes of Listing Rules 7.1 and 7.2 (Exception 13(b)); Parts 1.2 and 2J.1 and sections 200B, 200C, 200E and 259B(2) of the Corporations Act 2001 and for all other purposes, approval is given for the Company to adopt an employee incentive scheme titled “Paradigm Employee Performance Rights Plan” and for the issue of a maximum of 14,087,832 Performance /1464_7 1 Rights under the Plan, in accordance with the Plan Rules laid before the Meeting – a copy of which is available for inspection at the registered office of the Company (during normal business hours) and summarised in the Explanatory Statement accompanying this Notice.” A voting exclusion statement and voting prohibition statement apply to this Resolution. Please see below. 6. RESOLUTION 5 – ISSUE OF INCENTIVE PERFORMANCE RIGHTS TO DR DONNA SKERRETT To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, subject to the passing of Resolution 4, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue 1,000,000 Performance Rights to Donna Skerrett (or her nominee) under the Paradigm Employee Performance Rights Plan on the terms and conditions set out in the Explanatory Statement.” A voting exclusion statement and voting prohibition statement applies to this Resolution. Please see below. 7. RESOLUTION 6 – ISSUE OF INCENTIVE PERFORMANCE RIGHTS TO MR PAUL RENNIE To consider and, if thought fit, to pass the following resolution as an ordinary resolution: “That, subject to the passing of Resolution 4, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue 1,200,000 Performance Rights to Paul Rennie (or his nominee) under the Paradigm Employee Performance Rights Plan on the terms and conditions set out in the Explanatory Statement.” A voting exclusion statement and voting prohibition statement applies to this Resolution. Please see below. 8. RESOLUTION 7 – AMENDMENT TO CONSTITUTION To consider and, if thought fit, to pass the following resolution as a special resolution: “That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, approval is given for the Company to amend its Constitution as detailed in the Explanatory Statement accompanying this Notice.” 20230123 PAR - Notice of AGM 2023 (FINAL)b 2 Voting Prohibition Statements Resolution 1 – Adoption of Remuneration Report A vote on this Resolution must not be cast (in any capacity) by or on behalf of either of the following persons: (a) a member of the Key Management Personnel, details of whose remuneration are included in the Remuneration Report; or (b) a Closely Related Party of such a member. However, a person (the voter) described above may cast a vote on this Resolution as a proxy if the vote is not cast on behalf of a person described above and either: Resolution 4 – Adoption of Employee Performance Rights Incentive Plan (a) the voter is appointed as a proxy by writing that specifies the way the proxy is to vote on this Resolution; or (b) the voter is the Chair and the appointment of the Chair as proxy: (i) does not specify the way the proxy is to vote on this Resolution; and (ii) expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with the remuneration of a member of the Key Management Personnel. In accordance with section 250BD of the Corporations Act, a person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) (b) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Further, in accordance with section 200E(2A) of the Corporations Act, a vote on this Resolution must not be cast by any participants or potential participants in the Plan and their associates, otherwise the benefit of this Resolution will be lost by such a person in relation to that person’s future retirement. However, a vote may be cast by such a person if: 20230123 PAR - Notice of AGM 2023 (FINAL)b (a) the person is appointed as proxy by writing that specifies the way the proxy is to vote on the Resolution; and (b) it is not cast on behalf of the person or an associate of the person. 3 Resolution 5 – Issue of Incentive Performance Rights to Dr Donna Skerrett A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) (b) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: Resolution 6 – Issue of Incentive Performance Rights to Mr Paul Rennie (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. A person appointed as a proxy must not vote, on the basis of that appointment, on this Resolution if: (a) (b) the proxy is either: (i) a member of the Key Management Personnel; or (ii) a Closely Related Party of such a member; and the appointment does not specify the way the proxy is to vote on this Resolution. However, the above prohibition does not apply if: (a) the proxy is the Chair; and (b) the appointment expressly authorises the Chair to exercise the proxy even though this Resolution is connected directly or indirectly with remuneration of a member of the Key Management Personnel. Voting Exclusion Statements In accordance with Listing Rule 14.11, the Company will disregard any votes cast in favour of the Resolution set out below by or on behalf of the following persons: Resolution 4 – Adoption of Employee Performance Rights Incentive Plan A person who is eligible to participate in the employee incentive scheme or an associate of that person or those persons. Resolution 5 – Issue of Incentive Performance Rights to Dr Donna Skerrett Any person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive scheme in question (including Donna Skerrett) or an associate of that person or those persons. Resolution 6 – Issue of Incentive Performance Rights to Mr Paul Rennie Any person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the employee incentive scheme in question (including Paul Rennie) or an associate of that person or those persons. However, this does not apply to a vote cast in favour of the Resolution by: (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with the directions given to the proxy or attorney to vote on the Resolution in that way; or (b) the Chair as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and (ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way. 20230123 PAR - Notice of AGM 2023 (FINAL)b 4 Voting by proxy To vote by proxy, please complete and sign the enclosed Proxy Form and return by the time and in accordance with the instructions set out on the Proxy Form. In accordance with section 249L of the Corporations Act, Shareholders are advised that: each Shareholder has a right to appoint a proxy; the proxy need not be a Shareholder of the Company; and a Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the Shareholder appoints two proxies and the appointment does not specify the proportion or number of the member’s votes, then in accordance with section 249X(3) of the Corporations Act, each proxy may exercise one-half of the votes. Shareholders and their proxies should be aware that: if proxy holders vote, they must cast all directed proxies as directed; and any directed proxies which are not voted will automatically default to the Chair, who must vote the proxies as directed. Voting in person To vote in person, attend the Meeting at the time, date and place set out above. In accordance with the Corporations Act, the Company will not be sending hard copies of this Notice of Meeting to Shareholders, unless a Shareholder has requested a hard copy by 16 October 2023. This Notice of Meeting can be viewed and downloaded from the link set out below. Please also refer to the Online Meeting Guide attached to this Notice of Meeting for details on how to participate in the Meeting. The Company strongly encourages Shareholder to lodge a directed proxy form prior to the Meeting. Questions should also be submitted in advance of the Meeting as this will provide management with the best opportunity to prepare for the Meeting, for example, by preparing answers in advance to Shareholder questions. However, votes and questions may also be submitted during the Meeting. Virtual Meeting The Company is pleased to provide Shareholders with the opportunity to attend and participate in a virtual Meeting through an online meeting platform powered by Automic, where Shareholders will be able to watch, listen and vote online. Shareholders will be able to vote and ask questions at the virtual Meeting. Shareholders are also encouraged to submit questions in advance of the Meeting to the Company. Questions must be submitted in writing to Abby Macnish Company Secretary at ir@neuroscientific.com at least 48 hours before the Meeting. The Company will also provide Shareholders with the opportunity to ask questions during the Meeting in respect to the formal items of business as well as general questions in respect to the Company and its business. Attending the Meeting virtually To access the virtual Meeting: 1. 2. 3. 4. 5. 6. 7. Open your internet browser and go to investor.automic.com.au. Login with your username and password or click “Register” if you haven’t already created an account. Shareholders are encouraged to create an account prior to the start of the Meeting to ensure there is no delay in attending the virtual Meeting. After logging in, a banner will display at the bottom of your screen to indicate that the Meeting is open for registration. Click on “Register” when this appears. Alternatively, click on “Meetings” on the left-hand menu bar to access registration. Click on “Register” and follow the steps. Click on the URL to join the webcast where you can view and listen to the virtual Meeting. Note that the webcast will open in a separate window. Once the Chair of the Meeting has declared the poll open for voting click on "Refresh" to be taken to the voting screen. Select your voting direction and click "confirm" to submit your vote. Note that you cannot amend your vote after it has been submitted. 20230123 PAR - Notice of AGM 2023 (FINAL)b 5 For further information on the live voting process please see the “Registration and Voting Guide” at https://www.automicgroup.com.au/virtual-agms/. The Company will provide Shareholders with the opportunity to vote and ask questions at the Meeting in respect of the formal items of business as well as general questions in respect to the Company and its business. How do I create an account with Automic? To create an account with Automic, please go to the Automic website (https://investor.automic.com.au/#/home), click on ‘register’ and follow the steps. Shareholders will require their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) to create an account with Automic. Further information and support on how to use the platform is available on the share registry website – www.automic.com.au. It is recommended that you register to use the registry website well in advance of the Meeting to save time on the day of the Meeting. Should you have any difficulties, you can contact the registry by telephone on 1300 288 664 (within Australia) and +61 2 9698 5414 (overseas). You may still attend the Meeting and vote even if you have appointed a proxy. If you have previously submitted a Proxy Form, your attendance at the Meeting will not revoke your proxy appointment unless you actually elect to attend as a voting holder at the Meeting for which the proxy is proposed to be used, in which case, the proxy’s appointment will be deemed to be revoked with respect to voting. Should you wish to discuss the matters in this Notice please do not hesitate to contact the Company Secretary on +61 8 6382 1805. 20230123 PAR - Notice of AGM 2023 (FINAL)b 6 EXPLA NATORY S TATEMENT This Explanatory Statement has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions. 1. FINANCIAL STATEMENTS AND REPORTS In accordance with the Corporations Act, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2023 together with the declaration of the Directors, the Directors’ report, the Remuneration Report and the auditor’s report. The Company will not provide a hard copy of the Company’s annual financial report to Shareholders unless specifically requested to do so. The Company’s annual financial report is available on its website at www.paradigmbiopharma.com. 2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT 2.1 General The Corporations Act requires that at a listed company’s annual general meeting, a resolution that the remuneration report be adopted must be put to the shareholders. However, such a resolution is advisory only and does not bind the company or the directors of the company. The remuneration report sets out the company’s remuneration arrangements for the directors and senior management of the company. The remuneration report is part of the directors’ report contained in the annual financial report of the company for a financial year. The chair of the meeting must allow a reasonable opportunity for its shareholders to ask questions about or make comments on the remuneration report at the annual general meeting. 2.2 Voting consequences A company is required to put to its shareholders a resolution proposing the calling of another meeting of shareholders to consider the appointment of directors of the company (Spill Resolution) if, at consecutive annual general meetings, at least 25% of the votes cast on a remuneration report resolution are voted against adoption of the remuneration report and at the first of those annual general meetings a Spill Resolution was not put to vote. If required, the Spill Resolution must be put to vote at the second of those annual general meetings. If more than 50% of votes cast are in favour of the Spill Resolution, the company must convene a shareholder meeting (Spill Meeting) within 90 days of the second annual general meeting. All of the directors of the company who were in office when the directors’ report (as included in the company’s annual financial report for the most recent financial year) was approved, other than the managing director of the company, will cease to hold office immediately before the end of the Spill Meeting but may stand for re-election at the Spill Meeting. Following the Spill Meeting those persons whose election or re-election as directors of the company is approved will be the directors of the company. 20230123 PAR - Notice of AGM 2023 (FINAL)b 7 2.3 Previous voting results At the Company’s previous annual general meeting the votes cast against the remuneration report considered at that annual general meeting were less than 25%. Accordingly, the Spill Resolution is not relevant for this Meeting. 3. RESOLUTION 2 – RE-ELECTION OF DIRECTOR – DR DONNA SKERRETT 3.1 General Listing Rule 14.4 and clause 13.3(a) of the Constitution provide that, other than a managing director, a director of an entity must not hold office (without reelection) past the third annual general meeting following the director’s appointment or three years, whichever is the longer. Dr Donna Skerrett who has served as a Director since 3 July 2020 and was elected on 19 November 2020, retires by rotation and seeks re-election. 3.2 Qualifications and other material directorships Dr Donna Skerrett, has more than 30 years’ experience in transfusion and translational medicine. She brings a wealth of experience in clinical development and regulatory affairs. Dr Skerrett served previously as Chief Medical Officer at Mesoblast. She was director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York (2004 – 2011), and prior to that was associate director of Transfusion Medicine and director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital. She has previously chaired the New York State Council on Blood and Transfusion Services and served on the board of directors of the Fox Chase Cancer Center in Philadelphia, PA, and is currently a member of the Board of Visitors of Lewis Katz School of Medicine at Temple University. 3.3 Independence If re-elected the Board does not consider Dr Skerrett will be an independent Director. 3.4 Technical information required by Listing Rule 14.1A If Resolution 2 is passed, Dr Donna Skerrett will be re-elected to the Board as an Executive Director. In the event that Resolution 2 is not passed, Dr Skerrett will not join the Board as an Executive Director. The Company may seek nominations or otherwise identify suitably qualified candidates to join the Company. As an additional consequence, this may detract from the Board and Company’s ability to execute on its strategic vision. 3.5 Board recommendation The Board has reviewed Dr Skerrett’s performance since her appointment to the Board and considers that their skills and experience will continue to enhance the Board’s ability to perform its role. Accordingly, the Board unanimously supports the re-election of Dr Skerrett and recommends that Shareholders vote in favour of Resolution 2. 20230123 PAR - Notice of AGM 2023 (FINAL)b 8 4. RESOLUTION 3 – APPROVAL OF 7.1A MANDATE 4.1 General Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period. However, under Listing Rule 7.1A, an eligible entity may seek shareholder approval by way of a special resolution passed at its annual general meeting to increase this 15% limit by an extra 10% to 25% (7.1A Mandate). An ‘eligible entity’ means an entity which is not included in the S&P/ASX 300 Index and has a market capitalisation of $300,000,000 or less. The Company is an eligible entity for these purposes. As at the date of this Notice, the Company is an eligible entity as it is not included in the S&P/ASX 300 Index and has a current market capitalisation of $195,820,854 (based on the number of Shares on issue and the closing price of Shares on the ASX on 18 October 2023). Resolution 3 seeks Shareholder approval by way of special resolution for the Company to have the additional 10% placement capacity provided for in Listing Rule 7.1A to issue Equity Securities without Shareholder approval. For note, a special resolution is a resolution requiring at least 75% of votes cast by shareholders present and eligible to vote at the meeting in favour of the resolution. If Resolution 3 is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval. If Resolution 3 is not passed, the Company will not be able to access the additional 10% capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1A, and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1. 4.2 Technical information required by Listing Rule 7.1A Pursuant to and in accordance with Listing Rule 7.3A, the information below is provided in relation to Resolution 3: (a) Period for which the 7.1A Mandate is valid The 7.1A Mandate will commence on the date of the Meeting and expire on the first to occur of the following: (i) the date that is 12 months after the date of this Meeting; (ii) the time and date of the Company’s next annual general meeting; and (iii) the time and date of approval by Shareholders of any transaction under Listing Rule 11.1.2 (a significant change in the nature or scale of activities) or Listing Rule 11.2 (disposal of the main undertaking). 20230123 PAR - Notice of AGM 2023 (FINAL)b 9 (b) Minimum price Any Equity Securities issued under the 7.1A Mandate must be in an existing quoted class of Equity Securities and be issued for cash consideration at a minimum price of 75% of the volume weighted average price of Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before: (c) (i) the date on which the price at which the Equity Securities are to be issued is agreed by the entity and the recipient of the Equity Securities; or (ii) if the Equity Securities are not issued within 10 trading days of the date in Section 4.2(b)(i), the date on which the Equity Securities are issued. Use of funds raised under the 7.1A Mandate The Company intends to use funds raised from issues of Equity Securities under the 7.1A Mandate for the acquisition of new assets and or other investments, or as cash for general working capital purposes including the Company’s clinical trial program. (d) Risk of Economic and Voting Dilution Any issue of Equity Securities under the 7.1A Mandate will dilute the interests of Shareholders who do not receive any Shares under the issue. If Resolution 3 is approved by Shareholders and the Company issues the maximum number of Equity Securities available under the 7.1A Mandate, the economic and voting dilution of existing Shares would be as shown in the table below. The table below shows the dilution of existing Shareholders calculated in accordance with the formula outlined in Listing Rule 7.1A.2, on the basis of the closing market price of Shares and the number of Equity Securities on issue or proposed to be issued as at 18 October 2023. The table also shows the voting dilution impact where the number of Shares on issue (Variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 7.1A Mandate. Dilution Issue Price Number of Shares on Issue (Variable A in Listing Rule 7.1A.2) Shares issued – 10% voting dilution $0.348 $0.695 $1.04 50% decrease Issue Price 50% increase Funds Raised Current 281,756,625 Shares 28,175,662 Shares $9,805,130 $19,582,085 $29,387,215 50% increase 422,634,938 Shares 42,263,493 Shares $14,707,695 $29,373,127 $44,080,823 100% increase 563,513,250 Shares 56,351,325 Shares $19,610,261 $39,164,170 $58,774,431 20230123 PAR - Notice of AGM 2023 (FINAL)b 10 *The number of Shares on issue (Variable A in the formula)